Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Ho Hong

Showing results (31-40 of 94) with videos related to

Pageof 10
Sort By:
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Dermatology and Therapy|November 15, 2025
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand EczemaDavid Cohen, Anthony Bewley, Andreas Wollenberg, et al.
Dermatology and Therapy|June 27, 2026
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc AnalysisStephen Weidinger, Kristian Reich, Naiem Issa, et al.
Dermatology and Therapy|November 12, 2021
Efficacy of Dupilumab in Atopic Dermatitis: The Patient's PerspectiveMarjolein de Bruin-Weller, Joseph F Merola, Chih-Ho Hong, et al.
Dermatology and Therapy|July 14, 2026
Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical TrialsMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Dermatology and Therapy|April 25, 2026
Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 TrialAmy S Paller, Michael J Cork, H Chih-Ho Hong, et al.
The Journal of Dermatological Treatment|April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE studyBardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
Dermatologic Therapy|August 21, 2022
Management of moderate-to-severe plaque psoriasis with biologics: A treat-to-target position paperJensen Yeung, Marc Bourcier, Melinda J Gooderham, et al.
Dermatology and Therapy|April 25, 2025
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical TherapiesMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Pageof 10

Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
Journal of Cutaneous Medicine and Surgery|September 17, 2016
Review of Systemic Treatment Options for Adult Atopic DermatitisMelinda Gooderham, Charles W Lynde, Kim Papp, et al.
Dermatology and Therapy|November 15, 2025
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand EczemaDavid Cohen, Anthony Bewley, Andreas Wollenberg, et al.
Dermatology and Therapy|June 27, 2026
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc AnalysisStephen Weidinger, Kristian Reich, Naiem Issa, et al.
Dermatology and Therapy|November 12, 2021
Efficacy of Dupilumab in Atopic Dermatitis: The Patient's PerspectiveMarjolein de Bruin-Weller, Joseph F Merola, Chih-Ho Hong, et al.
Dermatology and Therapy|July 14, 2026
Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical TrialsMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Dermatology and Therapy|April 25, 2026
Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 TrialAmy S Paller, Michael J Cork, H Chih-Ho Hong, et al.
The Journal of Dermatological Treatment|April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE studyBardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
Dermatologic Therapy|August 21, 2022
Management of moderate-to-severe plaque psoriasis with biologics: A treat-to-target position paperJensen Yeung, Marc Bourcier, Melinda J Gooderham, et al.
Dermatology and Therapy|April 25, 2025
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical TherapiesMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Pageof 10